CN104257941A - Powder for external use for treating upper respiratory infection - Google Patents
Powder for external use for treating upper respiratory infection Download PDFInfo
- Publication number
- CN104257941A CN104257941A CN201410528348.8A CN201410528348A CN104257941A CN 104257941 A CN104257941 A CN 104257941A CN 201410528348 A CN201410528348 A CN 201410528348A CN 104257941 A CN104257941 A CN 104257941A
- Authority
- CN
- China
- Prior art keywords
- upper respiratory
- powder
- treatment
- respiratory tract
- aloe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/28—Mercury; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a powder for external use for treating upper respiratory infection. The powder for external use comprises the following components: nano silver, pearl powder, sulphur, aloe and calomel. The powder for external use is safe and efficient, has broad-spectrum antimicrobial treatment effects and can quickly infiltrate the skin to reach a target part, thereby achieving a sterilization function. The powder for external use takes the nano silver and pearl powder as main drugs, and further comprises the sulphur, the aloe and the calomel, so that the effects are remarkable, the drug effect is lasting; through the adoption of the nano silver, the drug resistance is avoided, and the toxic or side effects and irritating allergic phenomena are avoided.
Description
Technical field
The present invention relates to a kind of medicine, particularly a kind of external pulvis for the treatment of upper respiratory tract infection.
Background technology
Upper respiratory tract infection is the general name comprising nasal cavity, pharynx or acute throat inflammation, and incidence rate is higher.Adult is annual to be occurred 2 ~ 4 times, and child's incidence rate is higher, annual 6 ~ 8 times.The whole year all can fall ill, and winter-spring season is more.
Upper respiratory tract infection has 70% ~ 80% to be caused by virus.Comprise rhinovirus, coronavirus, adenovirus, influenza and parainfluenza virus, respiratory syncytial virus, echovirus, Coxsackie virus etc.The upper sense of 20% ~ 30% is separately had to be caused by antibacterial.Bacteriological infection can direct infection or after being secondary to viral infection, be the most common with Hemolytic streptococcus, being secondly hemophilus influenza, streptococcus pneumoniae, staphylococcus etc., is occasionally gram-negative bacteria.
Current treatment is treated in this disease in the market, western medicine result is not very good, the different thus upper respiratory tract infection patient of the pathogenic microorganism due to upper respiratory tract infection each enter showed symptom also different.Thus, general treatment principle is topical therapeutic clinically, antibiotic antiinflammatory, atomization or the treatment of smoked gas, or adopts Chinese medicine to nurse one's health, but curative effect is not clearly, takes effect slow.
Summary of the invention
For the defect existed in prior art, the object of the present invention is to provide a kind of external pulvis for the treatment of upper respiratory tract infection.
The technical solution adopted in the present invention is:
Treat an external pulvis for upper respiratory tract infection, comprise following component: nanometer silver 0.1 ~ 40g, Margarita powder 0.1 ~ 40g, sulfur 0.1 ~ 20g, Aloe 0.1 ~ 20g, Calomelas 0.1 ~ 20g.
Further, a kind of external pulvis for the treatment of upper respiratory tract infection comprises following component: nanometer silver 0.1 ~ 20g, Margarita powder 0.1 ~ 15g, sulfur 0.1 ~ 15g, Aloe 0.1 ~ 15g, Calomelas 0.1 ~ 15g.
Further, a kind of external pulvis for the treatment of upper respiratory tract infection comprises following component: nanometer silver 0.1 ~ 3g, Margarita powder 0.1 ~ 3g, sulfur 0.1 ~ 10g, Aloe 0.1 ~ 10g, Calomelas 0.1 ~ 10g.
Further, described nanometer silver particle diameter is 1 ~ 70nm.
Further, a kind of preparation method for the treatment of the external pulvis of upper respiratory tract infection comprises the following steps:
The first step: adopt super micron mill to pulverize sulfur, Aloe and Calomelas, cross 400 ~ 200 mesh sieves, obtain component A;
Second step: nanometer silver, Margarita powder and described component A are adopted mixer mixing 0.20 ~ 2 hour, obtain hybrid medicine;
3rd step: loaded by hybrid medicine in nano-cloth, finally packs to obtain finished product by the nano-cloth that hybrid medicine is housed.
Further, the nano-cloth that hybrid medicine is housed described in can direct percutaneous dosing.
External pulvis of the present invention safety, efficient, the curative effect with broad-spectrum antiseptic, skin permeation of the present invention can reach target site fast, plays the object of sterilization sterilizing.External pulvis of the present invention for principal agent, is equipped with sulfur, Aloe, Calomelas composition with nanometer silver and Margarita powder.In side, nanometer silver is received and is had strong suppression and killing action to tens of kinds of pathogenic microorganism such as escherichia coli, gonococcus, chlamydia trachomatiss, and can not produce drug resistance; In side, Margarita powder can strengthen lymphocyte activity, and promote lymphocyte growth, enhancing immunity, described Margarita powder has the effects such as arresting convulsion of calming the nerves, improving eyesight removing nebula, removing toxic substances and promoting granulation in the traditional Chinese medical science; The two is monarch drug altogether.In side, sulfur is warm in nature, has eliminating stagnation parasite killing, restrains antipruritic, effect of reducing swelling and alleviating pain; Skin ulcer parasite killing treated by Calomelas; Aloe has the effect of antiinflammatory, sterilization, hemostasis, analgesia, detumescence, antipruritic, rehabilitation, regeneration, antiallergic, accelerating wound healing; Three is minister.
Be very effective of the present invention, lasting medicine, employing nanometer silver, can not produce drug resistance.The present invention has no side effect and zest anaphylactoid phenomenon.Hybrid medicine of the present invention directly through nano-cloth contact percutaneous drug delivery, can ensure hybrid medicine effective rate of utilization.Medicine of the present invention is through nano-cloth slow releasing, and be easy to control, blood drug level is held time length, evident in efficacy.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is further elaborated.
Embodiment 1
Treat an external pulvis for upper respiratory tract infection, comprise following component:
Nanometer silver 1g, Margarita powder 1g, sulfur 2g, Aloe 2g, Calomelas 1g;
Described nanometer silver particle diameter is 25nm.
Preparation method of the present invention comprises the following steps:
The first step: adopt super micron mill to pulverize sulfur, Aloe and Calomelas, cross 200 mesh sieves, obtain component A;
Second step: adopt mixer to mix 1 hour nanometer silver, Margarita powder and described component A, obtain hybrid medicine;
3rd step: loaded by hybrid medicine in nano-cloth, finally packs to obtain finished product by the nano-cloth that hybrid medicine is housed.
Experimental example 2
Treat an external pulvis for upper respiratory tract infection, comprise following component:
Nanometer silver 2g, Margarita powder 2g, sulfur 2g, Aloe 2g, Calomelas 5g;
Described nanometer silver particle diameter is 30nm.
Preparation method of the present invention comprises the following steps:
The first step: adopt super micron mill to pulverize sulfur, Aloe and Calomelas, cross 200 mesh sieves, obtain component A;
Second step: adopt mixer to mix 0.20 hour nanometer silver, Margarita powder and described component A, obtain hybrid medicine;
3rd step: loaded by hybrid medicine in nano-cloth, finally packs to obtain finished product by the nano-cloth that hybrid medicine is housed.
Experimental example 3
Treat an external pulvis for upper respiratory tract infection, comprise following component:
Nanometer silver 20g, Margarita powder 3g, sulfur 3g, Aloe 15g, Calomelas 2g;
Described nanometer silver particle diameter is 40nm.
Preparation method of the present invention comprises the following steps:
The first step: adopt super micron mill to pulverize sulfur, Aloe and Calomelas, cross 200 mesh sieves, obtain component A;
Second step: adopt mixer to mix 2 hours nanometer silver, Margarita powder and described component A, obtain hybrid medicine;
3rd step: loaded by hybrid medicine in nano-cloth, finally packs to obtain finished product by the nano-cloth that hybrid medicine is housed.
The therapeutic effect of the present invention to the pharyngolaryngitis for the treatment of upper respiratory tract infection is further illustrated below by clinical practice.
According to theory of Chinese medical science, swallow the pass into stomach, larynx is the door of lung, and the heresy of diseases caused by exogenous pathogenic factor enters lung and easily hinders larynx, and improper diet enters stomach and is vulnerable to pharynx, and throat is the ground that evil malicious good leaching is stayed for a long time.The pharyngolaryngitis cause of disease is clinical inside and outside dividing, and exopathogenic factor mostly is the heresy be affected by the cold, the heresy of strongly fragrant heat-transformation of a specified duration or wind heat, and " Wenbing Tiaobian, Detailed Analysis of Epidemic Warm Diseases " is said " warm pathogen tend to attack the upper orifices, attacking the lung first ", and throat stands in the breach and experiences pathogenic warmth on occupying; Endogenous cause of ill mostly is the ferritic deficiency of YIN, stir-fry is decocted, stagnation of phlegm-heat again, the moon of upper bright throat or with the passing of time consumption impairing the lung kidney addicted to food is pungent, cause hyperactivity of deficient fire, consumption of body fluid by heat becomes expectorant, expectorant heat follow through on disturb throat, clean the street failure caused by, pathology as Golden Mirror of Medicine opinion sore throat is said: " lost for a long time by kidney yin; flaming up of the ministerial fire, disappear bright lung gold, and respectful clearly making is not all right ".
Clinical manifestation symptom one: larynx sense is uncomfortable
Comprise foreign body sensation, burn feeling, dry sensation, what have still has dull pain sense, above sense of discomfort say more sing more after particularly evident, through have a rest after symptom can alleviate or disappear.
Clinical manifestation symptom two: sounding changes
Can from hoarse, " crude ", hoarseness, until cry out completely.The conscious speech of patient is comparatively light more weak, tone step-down, dull effort, and these symptoms alleviate to some extent or disappear after unvoicing, but it is existing to appear again again after recovery throat, and the fashion time difference, again and again, the course of disease is very long, makes patient feel worried to sounding.Hoarseness is mute is topmost symptom, and sound step-down sinks, and coarse, it is heavier that morning plays symptom, increase with activity, expectoration throat portion secretion and taking a turn for the better gradually, be deteriorated again secondary morning, after unvoicing, hoarseness alleviates later, many speeches make exacerbation of symptoms again, in intermittent, with the passing of time develop into persistence.
Clinical manifestation symptom three: clear larynx of coughing
Talk or before performance, often have and think the endocrine clear larynx sound of expectoration larynx, throat portion secretion increases, and often feels have expectorant to adhere to, and whenever speaking, must cough to remove thickness sputum, this kind of situation, patient's yell excessively caused often.On can not cough how much secretions, this dry cough but becomes custom nasal obstruction, rhinorrhea for a long time, mouth breathing, and inflammation secretions stimulates throat's mucosa etc., all easily make vocal cords edema, hyperemia, time has been grown and can cause pachyderma circumscripta or vocal nodule, even develops into polyp, produces hoarseness.
Three types can be divided into according to the pathological change of pharyngolaryngitis
Chronic simple laryngitis: larynx mucous hyperemia, redness, under mirror, mucosa and submucous tissue are congested, edema, and have some lymphocytic infiltrations, basement membrane is broadening, change is loose.
Chronic hypertrophic laryngitis: larynx mucosa, under mirror, mucous epithelium thickens, and can have squamous metaplasia, and has keratinization phenomenon; Under mucosa, the obvious hypertrophy of fibrous tissue, has large amount lymphocyte, plasmocyte infiltrating, even forms lymph follicle.
Atrophic laryngitis: larynx mucosal atrophy is thinning, dry and shinny, vocal cords are thinning, tension reduction.Proliferation of fibrous tissue under visible mucosa under mirror, mucosal atrophy and body of gland atrophy, disappearance, the squamous epithelial cancer that ciliated columnar epithelium is given birth to by change replace.Vocal nodule is a type of chronic laryngitis, how because of improper and cause excessively or with sound with sound for a long time.Brief summary multidigit is in the center of vocal cords membranous part.From the beginning of time, brief summary is soft and redly, wherein congested, the interstitial edema of vasodilation.Subsequently, because there is fibrosis and vitreous degeneration, the epithelium acanthosis on surface, and have keratinization, thus brief summary becomes solid and is pale asphyxia.
One. Differential Diagnosis
1, hoarse is topmost symptom, and sound step-down is heavy, coarse, and it is heavier that morning plays symptom, increases with activity later, expectoration throat portion secretion and taking a turn for the better gradually, be deteriorated again secondary morning, after unvoicing, hoarseness alleviates, many speeches make exacerbation of symptoms again, in intermittent, with the passing of time develop into persistence.
2, secretions increases, and often feels have expectorant to adhere to, and whenever speaking, must cough to remove thickness sputum.
3, throat is dry, sense laryngalgia when speaking.
Two. the selection of case
Case all be can be used as the patient meeting above-mentioned disease observe, especially weak and sickly, middle-aged and elderly people, women are observed as first-selected case especially; The method of observing then carries out complete observation by the method for hoping, asking, hearing, cutting to patient; And, sex of all ages for the heavier patient of the state of an illness, without exception as the direct study subject observing treatment.
Three. administrated method
According to the severe extent of pharyngolaryngitis patient, the length of sick time, the nano-cloth that hybrid medicine is housed directly is worn on cervical region, ensure that nano-cloth directly contacts skin of neck, described hybrid medicine directly through nano-cloth contact skin percutaneous dosing, can ensure hybrid medicine utilization rate.Medicine of the present invention is through nano-cloth slow releasing, and be easy to control, blood drug level is held time length, and the present invention carries out observing and Outcome measure a course for the treatment of.
Four. curative effect determinate standard
Curative effect judging standard:
With reference to " Chinese medical disease Standardization of diagnosis and curative effect ":
Cure: red and swollen, rotten to the corn, cough the symptoms such as pain, dysphagia and disappear completely;
Effective: red and swollen, rotten to the corn, cough the symptoms such as pain, dysphagia and obviously alleviate;
Do not heal: symptom and clinical sign are without obvious change.
Five. clinical treatment outcome
Medicine of the present invention, through carrying out wearings treatment to all kinds of pharyngolaryngitis patient 239 examples of accepting for medical treatment altogether in 2009 ~ 2014 years 5 years, wherein male 187 example, women 202 is routine, and the age is 16 ~ 78 years old; Its clinical treatment outcome, according to above-mentioned domestic unified criterion of therapeutical effect statistical computation is: healing (more than 2 years non-recidivists are observed in drug withdrawal) 98 example, and cure rate is 41%; Effectively (more than 1 year non-recidivist is observed in drug withdrawal) 113 is routine, and obvious effective rate is 47.3%; (take medicine 3 courses for the treatment of, symptom does not alleviate) 28 of not healing is routine, inefficiency 11.7%; Total effective rate is 88.3%, there are no any toxic and side effects and stimulation phenomenon.
Model case
Huang, 32 years old, female, clinical symptoms with throat excessively, there is congested, vocal nodule and polyp of vocal cord, during inspection, visible lung marking increases the weight of, and is diagnosed as chronic pharyngolaryngitis.Therapeutic scheme: 1 course for the treatment of of medicine of wearing the embodiment of the present invention 1.Therapeutic outcome: voice recovers normal, vocal nodule and polyp of vocal cord are eliminated, and lung marking obviously improves.
Zhao, 28 years old, female, clinical symptoms is pharyngeal have dry overworked, scorching hot, gradually have pain, increase the weight of when swallowing, excessive saliva, is diagnosed as chronic pharyngolaryngitis.Therapeutic scheme: 1 course for the treatment of of medicine of wearing the embodiment of the present invention 1.Therapeutic outcome is pharyngeal dryly itches, scorching hot, pain symptom disappears, and swallow normal, saliva is normal, has thoroughly eradicated focus.
Week certain, 48 years old, man, clinical symptoms red swelling and pain of throat, various focusing depths represented, antiadoncus, food and saliva be all difficult to swallow, throat has expectorant sense, but can not cough expectorant, throat companion retch.Therapeutic scheme: 2 courses for the treatment of of medicine of wearing the embodiment of the present invention 1, pharyngolaryngitis symptom significantly disappears, gingivitis symptom is improved, and throat redness obviously disappears.
King so-and-so, 26 years old, man, clinical symptoms red swelling and pain of throat, food and saliva are all difficult to hypopharynx therapeutic scheme: 3 courses for the treatment of of medicine of wearing the embodiment of the present invention 1, pharyngolaryngitis symptom obviously reduces, and throat redness obviously disappears, and takes food accessible again.
The above; it is only most preferred embodiment of the present invention; not any pro forma restriction is done to the present invention; any those of ordinary skill in the art; do not departing under technical solution of the present invention ambit; utilize the method content of above-mentioned announcement to make many possible variations and modification to technical solution of the present invention, all belong to the scope of claims protection.
Claims (6)
1. treat an external pulvis for upper respiratory tract infection, it is characterized in that comprising following component:
Nanometer silver 0.1 ~ 40g, Margarita powder 0.1 ~ 40g, sulfur 0.1 ~ 20g, Aloe 0.1 ~ 20g, Calomelas 0.1 ~ 20g.
2. a kind of external pulvis for the treatment of upper respiratory tract infection according to claim 1, is characterized in that comprising following component: nanometer silver 0.1 ~ 20g, Margarita powder 0.1 ~ 15g, sulfur 0.1 ~ 15g, Aloe 0.1 ~ 15g, Calomelas 0.1 ~ 15g.
3. a kind of external pulvis for the treatment of upper respiratory tract infection according to claim 1, is characterized in that comprising following component: nanometer silver 0.1 ~ 3g, Margarita powder 0.1 ~ 3g, sulfur 0.1 ~ 10g, Aloe 0.1 ~ 10g, Calomelas 0.1 ~ 10g.
4. a kind of preparation method for the treatment of the external pulvis of upper respiratory tract infection according to claim 1, is characterized in that comprising the following steps:
The first step: adopt super micron mill to pulverize sulfur, Aloe and Calomelas, cross 400 ~ 200 mesh sieves, obtain component A;
Second step: nanometer silver, Margarita powder and described component A are adopted mixer mixing 0.20 ~ 2 hour, obtain hybrid medicine;
3rd step: loaded by hybrid medicine in nano-cloth, finally packs to obtain finished product by the nano-cloth that hybrid medicine is housed.
5. a kind of external pulvis for the treatment of upper respiratory tract infection according to claim 1, is characterized in that described nanometer silver particle diameter is 1 ~ 70nm.
6. a kind of external pulvis for the treatment of upper respiratory tract infection according to claim 4, the nano-cloth that hybrid medicine is housed described in it is characterized in that can direct percutaneous dosing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410528348.8A CN104257941A (en) | 2014-09-26 | 2014-09-26 | Powder for external use for treating upper respiratory infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410528348.8A CN104257941A (en) | 2014-09-26 | 2014-09-26 | Powder for external use for treating upper respiratory infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104257941A true CN104257941A (en) | 2015-01-07 |
Family
ID=52149598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410528348.8A Pending CN104257941A (en) | 2014-09-26 | 2014-09-26 | Powder for external use for treating upper respiratory infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104257941A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090105262A1 (en) * | 2007-08-10 | 2009-04-23 | Whiteford Jeffery A | Bridged polycyclic compound based compositions for coating oral surfaces in humans |
| CN101537109A (en) * | 2009-04-29 | 2009-09-23 | 宋安林 | Medicine for treating throat diseases and preparation method thereof |
| CN103071056A (en) * | 2013-01-09 | 2013-05-01 | 普洱市民族传统医药研究所 | Medicine for curing oral diseases |
-
2014
- 2014-09-26 CN CN201410528348.8A patent/CN104257941A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090105262A1 (en) * | 2007-08-10 | 2009-04-23 | Whiteford Jeffery A | Bridged polycyclic compound based compositions for coating oral surfaces in humans |
| CN101537109A (en) * | 2009-04-29 | 2009-09-23 | 宋安林 | Medicine for treating throat diseases and preparation method thereof |
| CN103071056A (en) * | 2013-01-09 | 2013-05-01 | 普洱市民族传统医药研究所 | Medicine for curing oral diseases |
Non-Patent Citations (6)
| Title |
|---|
| 《家庭健康医疗实用大百科》编委会: "《家庭健康医疗实用大百科》", 30 April 2010 * |
| 东方妙春: "《从头到脚话健康：自己是最好的医生》", 31 October 2008 * |
| 徐淑军等: "芦荟治疗鼻炎", 《中国民间疗法》 * |
| 易清安: "《神奇的芦荟健康美容》", 30 June 1999 * |
| 陈德兴: "《家庭常用中成药600种》", 31 August 1997 * |
| 陈颖健: "《当代热点科学技术浅说》", 30 November 2003 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103301254B (en) | Antibacterial liquid used for nasopharyal meatus and preparation method thereof | |
| CN103223019A (en) | Traditional Chinese medicine for treating rhinitis | |
| CN104840521A (en) | Pharmaceutical composition for treating rhinitis | |
| CN104800597A (en) | Traditional Chinese medicine composition for treating sphagitis | |
| CN103877288B (en) | A kind of chitosan nasopharynx biological medicinal membrane and preparation method thereof | |
| CN1294930C (en) | Medication for treating cough caused by inflammation of upper respiratory tract | |
| CN104257941A (en) | Powder for external use for treating upper respiratory infection | |
| CN102423387B (en) | Chinese medicine composition for treating oral ulcers | |
| CN104547128A (en) | Medicine for treating rhinitis | |
| CN116585404B (en) | External traditional Chinese medicine composition for treating adult simple skin pruritus and preparation method thereof | |
| CN104127668A (en) | Traditional Chinese medicinal preparation for curing chronic pharyngitis | |
| CN108186947A (en) | A kind of Chinese medicine composition and its preparation method and application | |
| CN103989929A (en) | Traditional Chinese medicine preparation for treating pharyngolaryngitis and preparation method thereof | |
| CN102205048A (en) | Pharmaceutical composition with function of moistening throat | |
| CN103623369B (en) | A kind of Chinese medicinal formulae for the treatment of tonsillitis, chronic pharyngitis | |
| CN107625872A (en) | A kind of pure Chinese medicinal preparation that can quickly effect a radical cure all kinds of rhinitis | |
| CN107753575A (en) | A kind of oral cavity ulcer powder and preparation method thereof | |
| CN104784384A (en) | Traditional Chinese medicine for treating pharyngitis | |
| CN102423389B (en) | Traditional Chinese medicine composition for treating canker sore | |
| CN106038665A (en) | Traditional Chinese medicine composition for treating chronic pharyngitis and preparation method | |
| CN103432223B (en) | Medicament for treating impetigo and preparation method thereof | |
| CN111568990A (en) | Composite medicine for treating allergic and chronic rhinitis and preparation method thereof | |
| CN102423391B (en) | Traditional Chinese medicine composition for treating oral ulcer | |
| CN104435414A (en) | Medicine liquid capable of promoting healing of internal hemorrhoid surgical wound and preparation method of medicine liquid | |
| CN105560533A (en) | Traditional Chinese medicine composition for treating throat disease and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150107 |
|
| RJ01 | Rejection of invention patent application after publication |